Interstitial nephritis is an inflammatory condition of the kidneys that targets the tissue surrounding the filtering tubules rather than the tiny blood-vessel clusters (glomeruli) that most people associate with kidney disease. The inflammation can appear suddenly, in which case it is called acute interstitial nephritis (AIN), or it can smolder for months to years as chronic interstitial nephritis. Medications are the trigger in the vast majority of biopsy-confirmed cases, but infections, autoimmune disorders, toxins, and even inherited gene mutations can also be responsible. What makes this condition especially tricky is that its symptoms are often vague and overlap with other causes of kidney injury, so it frequently goes unrecognized until a biopsy settles the question.
Why Drugs Are the Leading Cause
Drugs account for roughly 70% to 90% of biopsy-proven interstitial nephritis cases, with the exact proportion varying by region and healthcare setting.1PubMed. Medication-Induced Interstitial Nephritis in the 21st Century Antibiotics have traditionally topped the list of offenders, but the landscape has shifted over the past two decades. Proton pump inhibitors (the widely used acid-reducing pills like omeprazole and lansoprazole), nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen and naproxen), and a class of gut medications called 5-aminosalicylates now share the stage with antibiotics as common culprits.2PubMed. Medication-Induced Interstitial Nephritis in the 21st Century
The shift matters clinically because those older, antibiotic-driven cases tended to announce themselves with the so-called classic triad of fever, skin rash, and a rise in eosinophils (a type of white blood cell associated with allergic reactions). Presentations triggered by PPIs or NSAIDs look different: they are often “oligosymptomatic,” meaning few outward signs, and they show up more frequently in older adults.3Nephrology Dialysis Transplantation. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury A person taking a PPI for heartburn might have nothing more than a rising creatinine on routine blood work, with no rash and no fever. That silent presentation is one reason the condition is frequently missed or attributed to something else.
NSAIDs deserve special mention. Beyond the well-known hemodynamic kidney injury that NSAIDs can cause by reducing blood flow, they can also trigger a distinct form of AIN that often comes with heavy protein loss in the urine (nephrotic syndrome). About 80% of NSAID-related AIN cases involve this nephrotic-range proteinuria, and it has been linked most often to drugs like naproxen and ibuprofen.4J. Bras. Nefrol.. Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs The good news is that kidney function usually recovers once the drug is stopped.5J. Bras. Nefrol.. Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs Even newer selective NSAIDs (COX-2 inhibitors like celecoxib) are not immune from this risk: case reports document AIN with nephrotic syndrome from celecoxib in patients who had normal kidneys beforehand.6American Journal of Kidney Diseases. Nephrotic syndrome and interstitial nephritis associated with celecoxib
How the Immune System Turns on the Kidney
Drug-induced AIN is not a direct toxic effect of the medication on kidney cells. Instead, it is an immune reaction. The best-supported explanation involves a delayed-type hypersensitivity response, the same broad category of immune reaction responsible for contact dermatitis and some transplant rejections. The drug, or a fragment of it, binds to proteins along the tubular basement membrane and acts as a hapten, essentially a molecular flag that the immune system learns to recognize as foreign. That recognition kicks off a cascade in which T cells infiltrate the kidney’s interstitium, joined by eosinophils and plasma cells.7PubMed Central. The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma Cell-mediated immunity, rather than antibody-mediated attack, appears to be the dominant driver.8PubMed Central. Acute interstitial nephritis – a reappraisal and update.
This immune basis explains a few things patients find puzzling. First, AIN can develop weeks or even months after starting a drug, because the immune system needs time to mount the response. Second, the reaction is idiosyncratic: most people taking the same drug never develop kidney inflammation, because the hapten-recognition step depends on individual immune makeup. Third, once the immune response is established, re-exposure to the same drug (or sometimes a chemically related one) can provoke a faster and potentially more severe flare.
Immune Checkpoint Inhibitors and the Kidney
A newer class of cancer drugs has added a wrinkle to the drug-induced AIN story. Immune checkpoint inhibitors (ICIs), used widely against melanoma, lung cancer, and other malignancies, work by releasing the brakes on T cells so they can attack tumors. The trade-off is that those unleashed T cells sometimes attack normal tissue too. Kidney injury occurs in roughly 2% to 5% of patients on ICIs, and when a biopsy is performed the most common finding is acute tubulointerstitial nephritis.9PubMed. Immune checkpoint inhibitor-associated nephritis-treatment standard
Under the microscope, ICI-related AIN looks essentially the same as other drug-induced AIN, with T-cell-dominant infiltrates and sometimes granulomas.10British Journal of Cancer. Acute interstitial nephritis related to immune checkpoint inhibitors But the mechanism is subtly different. Rather than a hapten triggering the response, ICIs appear to break immune tolerance so that T cells begin targeting the kidney’s own proteins. The risk climbs when a patient receives dual checkpoint blockade (both CTLA-4 and PD-1 inhibitors) or when they are also taking other drugs already linked to AIN, such as PPIs or NSAIDs.11PubMed. Immune checkpoint inhibitor-associated nephritis-treatment standard
One encouraging finding: in a large study comparing outcomes, patients who developed AIN from checkpoint inhibitors actually had lower mortality than patients who had other forms of acute kidney injury during ICI therapy.12PubMed Central. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy This may reflect the fact that AIN is a treatable, potentially reversible lesion, whereas other forms of kidney damage during cancer treatment may signal more advanced disease. In small series, some patients have even been successfully rechallenged with the same ICI after recovering from AIN, though at least one case ended in recurrent kidney injury and fatal lung inflammation, so rechallenge decisions remain high-stakes.13PubMed Central. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy Single Center Experience of Management and Drug Rechallenge
Autoimmune and Systemic Causes
Drugs are not the only pathway. Several autoimmune and systemic conditions can produce interstitial nephritis independently. IgG4-related disease, an immune-mediated condition that can affect nearly any organ, frequently involves the kidneys, and tubulointerstitial nephritis is its most common renal manifestation.14PubMed Central. Overview of IgG4-Related Tubulointerstitial Nephritis and Its Mimickers In a study of 35 patients with IgG4-related tubulointerstitial nephritis, about three-quarters had kidney failure at presentation, and more than 80% had disease in other organs as well.15PubMed Central. Diagnosis of IgG4-related tubulointerstitial nephritis Biopsy in these patients shows dense plasma-cell infiltrates rich in IgG4-positive cells and a distinctive pattern of fibrosis.16Kidney International. IgG4-related kidney disease
TINU syndrome (tubulointerstitial nephritis and uveitis) is another specific variant in which kidney inflammation pairs with eye inflammation. It tends to strike younger patients, and there is a female preponderance, although gender differences may be weaker than early case series suggested.17PubMed Central. Tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review of its epidemiology, demographics and risk factors Elevated levels of antibodies against a modified form of C-reactive protein have been found in TINU patients as well as in people with Sjögren’s syndrome and lupus nephritis, hinting at shared autoimmune pathways.18PubMed Central. A Comprehensive Review of Tubulointerstitial Nephritis and Uveitis (TINU) Syndrome The eye symptoms sometimes appear before the kidney disease, sometimes after, and occasionally the two present together, which can make the diagnosis confusing if clinicians are not looking for the pairing.
Infections, though far less common than drug triggers in developed countries, remain a relevant cause. Bacterial, viral, and parasitic infections can all produce AIN during the course of a systemic illness.19PubMed Central. Infection associated acute interstitial nephritis; a case report Distinguishing infection-driven AIN from AIN caused by the antibiotic being used to treat the infection is a genuine clinical puzzle, and one that affects treatment decisions directly: you want to stop a culprit antibiotic, but you do not want to stop it if the infection itself is the real problem.20Clinical Kidney Journal. The diagnosis of acute interstitial nephritis caused by infection versus antibiotic-induced interstitial nephritis: a narrative review
Environmental Exposure and Aristolochic Acid
One of the more dramatic environmental causes of chronic interstitial nephritis involves aristolochic acid, a compound found in certain plants of the Aristolochia genus. The condition first gained attention in the 1990s when young Belgian women developed rapidly progressive kidney fibrosis after taking weight-loss pills that contained Chinese herbal extracts. Kidney biopsies showed a striking pattern: extensive interstitial fibrosis with very few inflammatory cells, plus tubular atrophy spreading from the outer cortex inward. Aristolochic acid was identified in the pills, and DNA adducts from the toxin were subsequently found in patients’ kidney and ureter tissue.21PubMed. Aristolochic acid and ‘Chinese herbs nephropathy’: a review of the evidence to date Animal studies later confirmed that aristolochic acid alone could reproduce the clinical picture, including a worrying risk of upper urinary tract cancers. The condition is now called aristolochic acid nephropathy and remains a concern in parts of the world where traditional herbal remedies containing Aristolochia species are still used.
Why Diagnosis Is Difficult
A kidney biopsy remains the gold standard for diagnosing AIN. The problem is that biopsies are invasive, carry a small bleeding risk, and are often not performed when the clinical picture is ambiguous. Standard blood and urine tests can suggest AIN but cannot confirm it. Eosinophils in the urine, once considered a hallmark, turn out to be neither sensitive nor specific enough to be relied upon. The result is that AIN is probably underdiagnosed, with many cases lumped in with “acute tubular necrosis” or simply labeled as unexplained kidney injury.
Research into urine biomarkers is trying to close that gap. Urine levels of two inflammatory molecules, TNF-alpha and IL-9, have shown promise: patients with biopsy-confirmed AIN consistently had higher levels of both compared to patients with other kidney diseases. In one study, adding these biomarkers to the diagnostic workup improved diagnostic accuracy well beyond what clinicians achieved using their prebiopsy clinical judgment alone.22PubMed Central. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis These biomarkers are not yet in routine clinical use, but they represent a clear path toward reducing the need for biopsy in straightforward cases.
Imaging can also help in specific situations. Gallium-67 scintigraphy, a nuclear medicine scan, has been explored as a way to distinguish AIN from acute tubular necrosis. In an experimental model, gallium uptake in the kidneys was dramatically higher in AIN than in tubular necrosis.23Nephrology Dialysis Transplantation. Ga-67 scintigraphy in the differential diagnosis between acute interstitial nephritis and acute tubular necrosis: an experimental study In clinical practice, however, gallium scanning is not perfect. At commonly used cutoff values, one study found sensitivity of about 61% and specificity of 75%.24PubMed Central. The use of gallium-67 scintigraphy in the diagnosis of acute interstitial nephritis Early work with gallium-68 PET scanning has shown that kidney-to-spine uptake ratios can separate AIN from tubular necrosis with decent accuracy, though the technique remains investigational.25Journal of Nuclear Medicine. Can Gallium-68 PET differentiate acute interstitial nephritis from acute tubular necrosis?
Treatment and the Urgency of Timing
The first and most important step in treating drug-induced AIN is simple in concept and sometimes hard in practice: stop the offending drug. When the trigger can be confidently identified and withdrawn, many patients recover a significant amount of kidney function on their own. The complication arises when multiple medications are suspects, or when the triggering drug is one the patient genuinely needs, such as a cancer immunotherapy agent or an antibiotic for a serious infection.
Steroids (typically prednisone or an equivalent) are the standard pharmacological treatment, and the timing of their introduction appears to matter a great deal. In one study, patients who received steroids within the first two weeks after the offending drug was withdrawn recovered kidney function significantly better than those whose steroid treatment was delayed by an average of about five weeks. Repeat biopsies in delayed-treatment patients showed progression to interstitial fibrosis, the scarring that makes damage permanent.26PubMed. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis That finding underscores a recurring theme: the longer the inflammation goes unchecked, the more scar tissue forms, and once the kidney scars, that loss of function is unlikely to come back.
For ICI-related AIN, the steroid question carries additional weight because steroids could theoretically blunt the anticancer immune response. Oncologists and nephrologists have to weigh the kidney benefit against the cancer risk, and practices vary. In small case series, most patients have been treated with steroids and ICI withdrawal, with improvement in kidney function in the majority of cases.27British Journal of Cancer. Acute interstitial nephritis related to immune checkpoint inhibitors
When Interstitial Nephritis Becomes Chronic
Chronic interstitial nephritis develops either when acute disease is not recognized and treated in time, or as the primary presentation of a slow-burning process. Autoimmune diseases, metabolic conditions, environmental toxins, and some medications (especially with long-term exposure) can all produce chronic tubulointerstitial injury. Unlike acute cases, chronic interstitial nephritis often does not have a single dramatic presentation. Kidney function drifts downward over months or years, and by the time it is recognized, substantial fibrosis may already be in place.
Tubular cells that are injured or chronically stressed send out signals that recruit inflammatory cells and activate fibroblasts in the surrounding interstitium. Those fibroblasts lay down collagen, the kidney stiffens with scar tissue, and the scarring itself triggers further tubular injury, creating a self-perpetuating cycle.28PubMed Central. Tubulointerstitial injury and the progression of chronic kidney disease For chronic forms, biopsy is needed less often because available treatments are mostly supportive: controlling blood pressure, managing fluid balance, avoiding further nephrotoxic exposures, and slowing progression toward dialysis or transplant.
The Genetic Side of Tubulointerstitial Disease
Not all interstitial nephritis is acquired. Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a group of inherited conditions now considered one of the more common single-gene causes of chronic kidney disease, likely accounting for around 5% of all monogenic kidney disease.29Nephrology Dialysis Transplantation. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease Mutations in two genes, UMOD and MUC1, are responsible for the majority of cases.
In a large study of over 700 patients from nearly 600 families, UMOD mutations were found in about 38% of families and MUC1 mutations in about 35% of those who tested negative for UMOD changes.30Kidney International. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1 The two subtypes have different clinical personalities. UMOD-related disease is strongly associated with gout, with patients developing gout at a median age of 30 years, whereas MUC1 patients tend to be spared from gout until much later in life. On the other hand, patients with MUC1 mutations reach end-stage kidney disease earlier, at a median age of 46 compared with 54 for UMOD patients.31Kidney International. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1
The biopsy in ADTKD shows interstitial fibrosis and tubular damage without the inflammatory infiltrate typical of drug-induced or autoimmune AIN, and the urinalysis is characteristically bland, meaning little or no protein and no blood. That bland urinalysis is actually a diagnostic clue: in a patient with a family history of progressive kidney disease and an unremarkable urine dipstick, ADTKD should be on the differential. Genetic testing, increasingly accessible through next-generation sequencing panels, has made identification more straightforward than it was even a decade ago. Rarer mutations in genes like REN, SEC61A1, DNAJB11, and HNF1B account for additional cases.32Nephrology Dialysis Transplantation. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease
A Condition That Was Overlooked for a Long Time
The interstitium was one of the first parts of the kidney to be linked to chronic kidney disease, as far back as 1827, but the research community quickly became more interested in glomerular and vascular injuries and left interstitial diseases relatively unstudied for decades. Interstitial lesions resurfaced in the literature in the mid-1800s as a complication of scarlet fever, and the term “acute interstitial nephritis” was formally introduced in 1898. For much of the twentieth century, chronic interstitial nephritis was assumed to be caused mostly by kidney infections (pyelonephritis). It was not until kidney biopsy became routine in the 1950s that researchers recognized interstitial disease as its own independent category, largely through studies of patients taking large amounts of analgesics. The name “tubulointerstitial nephritis” was coined in 1963 to acknowledge that tubular cells are active participants in the disease, not bystanders.33PubMed. Interstitial Nephritis: Wherefrom, Wherein, and Whereto
That historical sidelining has echoes today. Interstitial nephritis still receives less attention in medical training than glomerular diseases, and its diagnosis continues to rely heavily on biopsy at a time when many eligible patients never get one. The emergence of new triggers, from PPIs to checkpoint inhibitors, and the growing recognition of genetic forms like ADTKD suggest the condition is more common than the medical community has traditionally appreciated. Research into noninvasive diagnostics, including urine biomarkers and advanced nuclear imaging, may eventually shift the diagnosis earlier and reduce the number of cases that silently progress to irreversible kidney damage.